High dose photon/proton XRT can be delivered to the spinal region for treatment of sarcomas.
Treatment-related morbidity to date appears acceptable.
These treatment results in such challenging tumors are very encouraging.
Will have to await additional follow-up, especially for the chordomas
Preferable to radiate at time of initial presentation
Potential concern about late sacral nerve toxicity in patients receiving 77.4 Gy
The superior conformality of proton radiotherapy offers promise in the treatment of spine and paraspinal sarcomas, as it can achieve relatively high doses to the tumor and tumor bed, while sparing nearby critical structures.
The preliminary local failure rate (12% at 36 months median f/u) compares favorably to historical local failure rates of over 40%.
Longer follow-up will help define whether local control is maintained and whether there will be a late-toxicity benefit.
May 17, 2012 - For patients with metastatic non-adipocytic soft-tissue sarcoma, progressing in spite of previous chemotherapy, pazopanib improves progression-free survival, according to the results of a phase 3 study published online May 16 in The Lancet.